Torbicki A,Konstantinides S,Perrier A,et al.Guidelines on the diagnosis and management of acute pulmonary embolism:the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of European Society of Cardiology[J].Eur Heart J,2008,29(18):2276-2315.
[3]
Lyman GH,Khorana AA,Falanga A,et al.American Society of Clinical Oncology guideline:Recommendations for venous thromboembolism prophylasis and treatment in patients with cancer[J].J Clin Oncol,2007,25(34):5490-5505.
[4]
Yoo HH,De Paiva SA,Silveira LV,et al.Logistic regression analysis of potential prognostic factors for pulmonary thromboembolism[J].Chest,2003,123(3):813-821.
[5]
KhoranaAA.The NCCN clinical practice guidelines on venous thromboembolic disease:Strategies for improving VTE prophylaxis in hospitalized cancer patients[J].Oncologist,2007,12(11):1361-1370.
[6]
Zachariski LR,Prandoni P,Monreal M.Warfarin versus low-molecular-weight heparin therapy in cancer patients[J].The Oncologist,2005,10(1):72-79.
Cosgrove RH,Zacharski LR,Racine E, et al.Improved cancer mortality with low-molecular-weight heparin treatment:A review of the evidence[J].Semin Thromb Hemost,2002,28(1):79-87.